Particularly, p52 appears to be necessary for sustaining and potentially initiating the activity of MM specific regulatory elements that potentiate pro-oncogenic super-enhancer and target driver gene cis-regulatory pairings like BCL2 and RGS1. This evidence concerns the gene NFKB2 and Miyoshi myopathy.